Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
Among inpatients with restrictive eating disorders, those with large, rapid or long-duration weight loss appear to have greater illness severity regardless of their current weight, a study has found.
Incident hypertension is associated with hypertriglyceridemic waist-to-height ratio (HWHtR) and its dynamic status, according to a study of rural Chinese men. HWHtR may be used as a marker for interventions aiming to lower hypertension incidence in men.
The presence of maternal stress or anxiety disorders prior to or following childbirth may be detrimental to children, bearing an increased hazard of fractures in early life, as shown in a recent study.
Graphic warning labels seem to steer the attention of adolescents towards images over text but do not influence the amount of overall attention paid to the warnings, a recent study has shown.
The interruption of thienopyridine treatment within 6 months of percutaneous coronary intervention (PCI) is common and may lead to greater risks of major adverse cardiac and cerebrovascular events (MACCE), a recent study has found.
Patients suffering from cryptogenic pyogenic liver abscess (PLA) are at a greater risk of developing colorectal cancer, reports a recent meta-analysis.
Individuals exposed to elevated blood pressure (BP) levels from young adulthood to midlife are likely to have poor gait and cognitive performance in midlife, a study suggests. Cerebral white matter hyperintensity moderates the relationship of cumulative BP exposure with gait but not with cognitive function.
Special Reports
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
At a Duopharma-sponsored symposium during the Diabetes Asia Conference 2019 at Hotel Istana, Kuala Lumpur, Professor Dato’ Dr Mafauzy Mohamed spoke about the role of biosimilar insulin glargine in improving access to diabetes treatment, presenting important evidence that affirms the quality, efficacy and safety of the biosimilar product.
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Saxagliptin 5 mg, dapagliflozin 10 mg FC tab
Fenofibrate 145 mg, simvastatin 20 mg FC tab
The latest research, clinical data and innovations in
ophthalmology were presented at the 2019 Annual Meeting of the American Academy
of Ophthalmology (AAO) in San Francisco, USA, held on 12−15 October 2019. As in
previous years, an international panel of renowned ophthalmologists attended
the meeting and contributed articles to Eye on AAO 2019 – an e-Bulletin series featuring
research highlights and hot topics presented at the meeting, with commentaries
on their relevance to clinical practice in the Asia Pacific and Latin American regions.
At a recent Boehringer Ingelheim-sponsored symposium held in conjunction with the 10th Malaysian Endocrine and Metabolic Society Annual Congress, two distinguished speakers spoke on the latest updates in glucose-lowering therapy for the treatment for type 2 diabetes mellitus (T2DM) and highlighted some important cardiovascular outcome trial results of these antidiabetic agents.
Conference Reports
Luspatercept promotes red blood cell (RBC) transfusion independence among low-risk myelodysplastic syndrome (MDS) patients, according to a longer-term analysis of the MEDALIST study presented at the recently concluded 61st Annual Meeting and Exposition of the American Society of Hematology (ASH 2019).
The impact of sacubitril plus valsartan compared with valsartan alone in reducing heart failure hospitalizations (HHF) in individuals with heart failure with preserved ejection fraction (HFpEF) appears to be greater in women than men, according to a subgroup analysis of the PARAGON-HF* trial.
In the treatment of stem cell transplant-ineligible patients with newly diagnosed multiple myeloma (MM), the addition of clarithromycin to lenalidomide and dexamethasone yields marked improvements in response rates that, however, do not equate to better survival, as shown in the results of the phase III GEM-Claridex trial.
Debulking tumour with two cycles of obinutuzumab prior to initiating frontline venetoclax therapy is effective for patients with absolute lymphocyte count (ALC) >25 × 109/L and lymph nodes <5 cm, with a success rate of >98 percent, and the addition of bendamustine to this therapy improves debulking for those with nodes 5–10 cm, according to a study presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH 2019).
Subcutaneous (SC) daratumumab (DARA) showed comparable performance to intravenous (IV) admission in patients with relapsed or refractory multiple myeloma (RRMM), according to a phase III, randomized, open-label, active-controlled multicentre study presented at the recently concluded 61st Annual Meeting and Exposition of the American Society of Haematology (ASH 2019).
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Multimedia
